Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Sartorius Acquires Stake in AllPure Technologies | Contract Pharma

What are you searching for?

Sign in
Breaking News

Sartorius Acquires Stake in AllPure Technologies

Expands portfolio of single-use components for biopharma applications

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Sartorius Stedim Biotech (SSB) has signed a contract to acquire majority stake in AllPure Technologies LLC, a start-up company based in New Oxford, PA that specializes in single-use components for biopharma applications. AllPure was established in 2010, and in 2013 had revenues of approximately $3 million with 25 employees. Financial terms were not disclosed.
 
Reinhard Vogt, member of SSB’s executive board said, “AllPure further completes our portfolio with innovative products that help our customers develop and manufacture their pharmaceutical drugs safer and more efficiently. I am really looking forward to working with the AllPure team and to all that we can accomplish together.”
 
“We are excited to leverage Sartorius Stedim’s impressive R&D capabilities so that we can accelerate the launch of new products from AllPure. And SSB’s global reach and industry relationships grant access to considerably more customers, especially in Europe and Asia, which have tremendous potential for AllPure’s products,” said Michael Zumbrum, president of AllPure.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics